Regulatory & safety
What is available today, and what is still under investigation.
This page was reviewed by the Scientific Director on 16 August 2026.
Current position
PEXT is presented as a Regenerative Powder within a cosmetic framework
PEXT is presented within the cosmetic framework applicable to its authorized intended topical use.
It is not presented as an approved drug, an injectable treatment, or a product intended to diagnose, treat, cure or prevent disease.
Classification is decided by six things
- Intended use
- Claims made
- Composition
- Route of administration
- Presentation
- Requirements of each jurisdiction
In the European Union, borderline classification decisions are made case by case. Availability, indications, claims and routes of administration may therefore vary by jurisdiction.
Two categories, often conflated
A cosmetic product and an investigational medicinal product are not the same thing
Commercially available today
Topical cosmetic and professional aesthetic formulations
Intended to support the appearance and condition of skin or scalp. This is where PEXT sits. Cosmetic claims must meet standards of legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making.
Under investigation
Investigational medicinal products
In the United States, the FDA states that exosome products intended to treat diseases or medical conditions require regulatory approval, and that there are currently no FDA-approved exosome products for such therapeutic use. Commercial cosmetic positioning must stay clearly separated from investigational medical research.
EU common criteria
The six standards a cosmetic claim has to meet
- Legal compliance
- Claims must comply with applicable law.
- Truthfulness
- Claims must not attribute characteristics the product does not have.
- Evidential support
- Claims must be supported by adequate and verifiable evidence.
- Honesty
- Claims must not go beyond what the available evidence supports.
- Fairness
- Claims must not denigrate competitors or legally used ingredients.
- Informed decision-making
- Claims must be clear enough for the average end user to make an informed choice.
Specific clarifications
Five things this site will not let you infer
- That a CosIng listing means approval
- An ingredient's appearance in the European Commission's CosIng database does not, by itself, constitute product authorization or proof of regulatory approval. It is an inventory of ingredient names.
- That fibronectin proves what is in the vial
- Fibronectin is not a universal exosome marker. Fibronectin alone cannot establish the identity, purity, concentration or biological activity of an EV preparation. Those require multi-parameter analytical evidence.
- That registered studies validate PEXT
- The existence of a registered clinical study does not establish that an intervention is safe, effective, approved or suitable for general clinical use. Studies of the wider EV field are not studies of PEXT.
- That “lyophilized” means stable
- Inadequate formulation or process conditions can cause aggregation, particle loss, membrane alteration or reduced bioactivity. Stability has to be demonstrated after reconstitution.
- That future EV technology is a product claim
- Engineered EV systems, RNA and gene-editing payloads, and delivery to difficult-to-reach tissues are research and development directions for the field. They are not claims for the currently marketed product.